FDA Brief

Warning letters Drugs

FDA warning letter to

Media Networks Sydney Pty. Limited

High riskIssued Sep 16, 2025Posted Sep 23, 2025Center for Drug Evaluation and Research (CDER)

FDA says Australia's Media Networks Sydney failed to answer drug records requests for OTC Combantrin Chocolate Squares.

What happened

FDA reviewed import records showing a shipment of Combantrin Chocolate Squares into the US on April 11, 2024, declared Media Networks Sydney as manufacturer. FDA sent an electronic request for records on May 28, 2024, and follow-ups through April 4, 2025, but says they went unanswered. FDA also contacted the firm on December 18, 2024, to announce an inspection; the firm said it had not started production in Australia and asked to reschedule, which FDA said contradicted the import records.

What FDA found

  1. The company did not answer FDA's electronic request for records or repeated follow-up requests.

    section 704(a)(4) of the FD&C Act, 21 U.S.C. 374(a)(4)
  2. FDA says refusing access to records is a prohibited act.

    section 301(e) of the FD&C Act, 21 U.S.C. 331(e)
  3. FDA said the firm's statement that it had not started production in Australia conflicted with import records showing drugs made at its facility were shipped to the US.

  4. FDA said drugs may be deemed adulterated when an owner delays, denies, limits, or refuses an inspection.

    section 501(j) of the FD&C Act

What FDA wants

FDA asks the company to respond in writing within 15 working days, either with information for FDA to assess or with a request to schedule an inspection.

Who should pay attention

  • US importers and distributors of Combantrin Chocolate Squares
  • retailers and brands sourcing OTC drugs from Australian manufacturers
  • drug companies whose FDA records requests or inspection scheduling could be delayed

This is a summary. Read the original letter on fda.gov.

Media Networks Sydney Pty. Limited's FDA history

  1. Media Networks Sydney Pty Limited

    Media Networks Sydney failed to properly list Mylanta 2go Antacid and Microlax Enema with FDA, making them misbranded.

    Low

Full company page

Similar letters to other companies

  1. Chongqing Qiancan Technology Co., Ltd.

    Chongqing Qiancan Technology, an API maker in China, refused FDA records requests; FDA placed its drugs on import alert 66-79.

    High risk
  2. Tianjin Healthcare Medical Technology Co., Ltd.

    Chinese API maker refused FDA records requests, and all its drugs now face a US import alert.

    High risk
  3. PReye, LLC

    FDA warned PReye, LLC that its unapproved eye drop PReye Vitamin SEE was made without sterile controls in an unclassified office.

    High risk
  4. Suretec Innovations, LLC

    Suretec Innovations failed manufacturing quality rules for OTC sanitizing wipes and did not list a private-label wipe.

    High risk